ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Abstract Number: 1344

Efficacy and Safety of JAK Inhibitors in Difficult to Treat Rheumatoid Arthritis in Clinical Practice
Abstract Number: 1345

Maternal and Infant Outcomes Following Abatacept Exposure During Pregnancy
Abstract Number: 1346

Semen Analysis of Patients with Psoriatic Arthritis, Axial Spondyloarthritis and Healthy Controls
Abstract Number: 1347

Continuing Biologic DMARDs During Pregnancy in Women with Rheumatic Disease Was Not Associated with Increased Unfavorable Pregnancy Outcomes, Serious Infections, and Adverse Effects of Vaccination
Abstract Number: 1348

Reproductive Outcomes for Women with Vasculitis
Abstract Number: 1349

Paternal Effects of Anti-TNFs in Inflammatory Arthritis
Abstract Number: 1350

Identification of ACR Guidelines for SLE Pregnancy Care in the Electronic Health Record
Abstract Number: 1351

HPV Vaccination in Adolescent and Young Adult Patients Seen in an Academic Rheumatology Center
Abstract Number: 1352

Similar Delivery Outcomes in Pregnant Patients with and Without Takayasu Arteritis – A Nationwide Inpatient Database Study
Abstract Number: 1353

Sexual Dysfunction in Women with Systemic Lupus Erythematosus: A Cross-Sectional Multicentre Study
Abstract Number: 1354

The Impact of Pregnancy Intention on Depression and Quality of Life in Women with Lupus
Abstract Number: 1355

Delivering Care for Pregnant Women with Rheumatic and Musculoskeletal Diseases in Ireland: Current Challenges and Practices
Abstract Number: 1356

Reproductive History and HPV Vaccination Awareness Among Women with Systemic Lupus Erythematosus and Rheumatoid Arthritis
Abstract Number: 1357

Systemic Lupus Erythematosus and Assisted Reproductive Technology: A Case Series and Systematic Literature Review
Abstract Number: 1358

Experiences and Attitudes Related to Assisted Reproductive Technologies Among Women with Systemic Rheumatic Disease

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].